United Therapeutics Corp (NASDAQ: UTHR). Notable positive changes in fundamentals have recently occurred: the consensus estimate for December, 2024 increased significantly, the consensus estimate for December, 2023 increased significantly, and significant quarterly earnings acceleration occurred.
Significant positive changes in investment behavior have recently occurred for United Therapeutics Corp (NASDAQ: UTHR): the stock’s recent price rise disrupted its longer term downtrend.
In light of these very positive signals we are reviewing our current Overall Rating of B. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
UTHR is expected to continue to be an important Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
United Therapeutics has a current Value Trend Rating of B (Positive). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. United Therapeutics has a slightly positive Power Rating of 64 and a good Appreciation Score of 70, leading to the Positive Value Trend Rating.
Recent Price Action
United Therapeutics Corp (NASDAQ: UTHR) stock closed at $228.38 on 11/14/23 after an increase of 1.3%. The stock is unchanged during the last week and has been strong relative to the market over the last nine months.
Be the first to comment